<unk> , administered in single doses from 150 mg to 1200 mg to adult volunteers, shows a linear kinetic, with Met I serum concentration approximately 4-fold higher than those of<unk> . The pharmacokinetic parameters of<unk>  and Met I are fully comparable after single and multiple doses, therefore there is no accumulation or metabolic activation after repeated administrations. Food does not significantly affect the absorption of<unk> . After oral administration,<unk>  is rapidly absorbed in the gastro-intestinal tract and the plasmatic peak concentration (Cmax) is reached after 30–60 minutes (Tmax) from consumption. The molecule is rapidly transformed through a first-pass metabolism to the biologically active metabolite Met I. The drug bioavailability by oral route is very good. The half-life is 3 hours and the plasma binding protein is 65%. With respect to pharmacokinetics in special populations, a study in 12 health volunteers (mean age 70 years) confirmed that pharmacokinetic parameters for both<unk>  and Met I were similar to those observed in younger adults (mean age 31 years). Moderate renal dysfunction in elder volunteers did not affect<unk>  and Met I pharmacokinetics.
Erdosteine
Chaperone 
Stanniocalcin
Neurite
Demineralized bone matrix
Cellulite
Hermaphrodite 
Hydroxyapatite